PAS
TBPH icon

Point72 Asia (Singapore)’s Theravance Biopharma TBPH Stock Holding History

Point72 Asia (Singapore)’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$24 Sell
2
-2,328
-100% -$29.4K ﹤0.01% 848
2025
Q2 		$25.7K Sell
2,330
-3,715
-61% -$36.1K ﹤0.01% 698
2025
Q1 		$54K Buy
+6,045
New +$56.3K 0.01% 564
2024
Q3 		– Sell
-9,057
Closed -$76.8K – 1311
2024
Q2 		$76.8K Sell
9,057
-2,749
-23% -$24.8K 0.02% 548
2024
Q1 		$106K Buy
+11,806
New +$109K 0.03% 629

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asia (Singapore)'s TBPH Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Theravance Biopharma (TBPH) stake by 100% in Q3 2025, selling an estimated $29.4K and leaving 2 shares worth $24. The position accounts for ﹤0.01% of the portfolio, ranked #848.

Point72 Asia (Singapore) first reported a position in TBPH in Q1 2024 and has held it in 5 quarters since. The position peaked at $106K in Q1 2024. 162 funds tracked by Wall St. Rank hold TBPH as of Q3 2025.

  • Point72 Asia (Singapore) held 2 shares of Theravance Biopharma worth $24 as of Q3 2025.
  • Point72 Asia (Singapore) sold 2,328 Theravance Biopharma shares in Q3 2025, an estimated $29.4K.
  • Theravance Biopharma made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #848 holding.
  • Point72 Asia (Singapore) first reported a position in Theravance Biopharma in Q1 2024 and has held it in 5 quarters since.
  • Point72 Asia (Singapore)'s Theravance Biopharma position peaked at $106K in Q1 2024.
  • 162 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.